Improved OS for Patients With HER2-Positive Uterine Serous Carcinoma Receiving Trastuzumab Plus Chemotherapy
It has been estimated that approximately 30% of patients with advanced uterine serous carcinoma have HER2-positive disease.
It has been estimated that approximately 30% of patients with advanced uterine serous carcinoma have HER2-positive disease.
The insulin-lowering properties of metformin, along with its effects on synthetic metabolism, were some of the rationales for its use as a cancer therapy.
This analysis represents the largest reported series of patients with early-stage vulvar cancer characterized by a negative sentinel lymph node biopsy.
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.